Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Feb-17 2:18 PM View:  | Schlesinger Sarah J. Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 55,508 | -- | -- | (100%) 55.51K to 0 | |
| 16-Feb-17 2:14 PM View: | Soni Manmeet Singh EVP, CFO & Treasurer | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 3,273 | -- | -- | (100%) 3.27K to 0 | |
| 16-Feb-17 2:18 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 220,444 | -- | -- | (100%) 220.44K to 0 | |
| 16-Feb-17 2:14 PM View: | Denner Alexander J Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 12,850,000 | -- | -- | (100%) 12.85M to 0 | |
| 16-Feb-17 2:17 PM View: | Haimovitz Jules Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 18,008 | -- | -- | (100%) 18.01K to 0 | |
| 16-Feb-17 2:16 PM View: | Riedel Norbert G Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 139,867 | -- | -- | (100%) 139.87K to 0 | |
| 16-Feb-17 2:15 PM View: | Bollag Daniel M Sr. VP, Reg. Affairs & Quality | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 126,352 | -- | -- | (100%) 126.35K to 0 | |
| 16-Feb-17 2:17 PM View: | Bickerstaff George Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 18,008 | -- | -- | (100%) 18.01K to 0 | |
| 16-Feb-17 2:17 PM View: | Herron Jennifer Lyn Exec V.P. Chief Comm'l Officer | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 450 | -- | -- | (100%) 0.45K to 0 | |
| 16-Feb-17 2:15 PM View: | Protopapas Anna Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 41,910 | -- | -- | (100%) 41.91K to 0 | |
| 16-Feb-17 2:16 PM View: | Cole Hugh M SVP, Chief Business Officer | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 42,834 | -- | -- | (100%) 42.83K to 0 | |
| 16-Feb-17 2:14 PM View: | Denner Alexander J Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 53,173 | -- | -- | (< 1%) 12.9M to 12.85M | |
| 16-Feb-17 2:15 PM View: | Panayiotopoulos Paris President and CEO Director | Ariad Pharmaceuticals Inc. (ARIA) | 16-Feb-17 | Disposition | 159,378 | -- | -- | (100%) 159.38K to 0 | |
| 16-Feb-17 2:18 PM View: | Schlesinger Sarah J. Director | Ariad Pharmaceuticals Inc. (ARIA) | 13-Feb-17 | Gift | 15,600 | -- | -- | (22%) 71.11K to 55.51K | |
| 01-Feb-17 4:55 PM View: | Haimovitz Jules Director | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Grant | 18,008 | -- | -- | 100% 0 to 18.01K | |
| 01-Feb-17 4:55 PM View: | Riedel Norbert G Director | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Grant | 18,008 | -- | -- | 15% 121.86K to 139.87K | |
| 02-Feb-17 4:41 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Option Exercise | 29,333 | -- | -- | 15% 200.14K to 229.48K | |
| 01-Feb-17 4:56 PM View: | Bickerstaff George Director | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Grant | 18,008 | -- | -- | 100% 0 to 18.01K | |
| 01-Feb-17 4:54 PM View: | Protopapas Anna Director | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Grant | 18,008 | -- | -- | 75% 23.9K to 41.91K | |
| 02-Feb-17 4:41 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Payment of Exercise | 9,610 | $23.82 | $228,886.00 | (4%) 229.48K to 219.87K | |
| 02-Feb-17 4:42 PM View: | Bollag Daniel M Sr. VP, Reg. Affairs & Quality | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Option Exercise | 29,333 | -- | -- | 26% 111.69K to 141.02K | |
| 02-Feb-17 9:39 AM View: | Denner Alexander J Director | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Grant | 18,008 | -- | -- | < 1% 12.89M to 12.9M | |
| 01-Feb-17 4:56 PM View: | Schlesinger Sarah J. Director | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Grant | 18,008 | -- | -- | 34% 53.1K to 71.11K | |
| 02-Feb-17 4:42 PM View: | Bollag Daniel M Sr. VP, Reg. Affairs & Quality | Ariad Pharmaceuticals Inc. (ARIA) | 31-Jan-17 | Payment of Exercise | 14,667 | $23.81 | $349,293.00 | (10%) 141.02K to 126.35K | |
| 17-Jan-17 5:06 PM View: | Panayiotopoulos Paris President and CEO Director | Ariad Pharmaceuticals Inc. (ARIA) | 17-Jan-17 | Payment of Exercise | 33,300 | $23.69 | $788,934.00 | (17%) 192.68K to 159.38K | (< 1%) |
| 17-Jan-17 5:06 PM View: | Panayiotopoulos Paris President and CEO Director | Ariad Pharmaceuticals Inc. (ARIA) | 13-Jan-17 | Option Exercise | 66,600 | -- | -- | 53% 126.08K to 192.68K | |
| 10-Jan-17 6:17 PM View: | Bollag Daniel M Sr. VP, Reg. Affairs & Quality | Ariad Pharmaceuticals Inc. (ARIA) | 09-Jan-17 | Option Exercise | 32,000 | $7.82 | $250,240.00 | 25% 129.4K to 161.4K | |
| 10-Jan-17 6:17 PM View: | Bollag Daniel M Sr. VP, Reg. Affairs & Quality | Ariad Pharmaceuticals Inc. (ARIA) | 09-Jan-17 | Market Option Sale (Planned) | 32,000 | $23.78 | $760,960.00 | (20%) 161.4K to 129.4K | (< 1%) |
| 25-Oct-16 4:07 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 24-Oct-16 | Market Sale (Planned) | 19,638 | $9.56 | $187,739.00 | (9%) 217.52K to 197.88K | (149%) |
| 05-Oct-16 4:17 PM View: | Bollag Daniel M Sr. VP, Reg. Affairs & Quality | Ariad Pharmaceuticals Inc. (ARIA) | 03-Oct-16 | Market Sale (Planned) | 47,384 | $13.46 | $637,812.00 | (27%) 176.79K to 129.4K | (77%) |
| 28-Sep-16 4:19 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 28-Sep-16 | Market Option Sale | 8,750 | $13.98 | $122,311.00 | (4%) 226.27K to 217.52K | (70%) |
| 28-Sep-16 4:20 PM View: | Bollag Daniel M Sr. VP, Reg. Affairs & Quality | Ariad Pharmaceuticals Inc. (ARIA) | 26-Sep-16 | Option Exercise | 10,000 | -- | -- | 6% 166.79K to 176.79K | |
| 28-Sep-16 4:19 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 26-Sep-16 | Option Exercise | 17,500 | -- | -- | 8% 208.77K to 226.27K | |
| 23-Sep-16 5:46 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 22-Sep-16 | Market Sale (Planned) | 20,000 | $13.43 | $268,536.00 | (9%) 228.77K to 208.77K | (77%) |
| 16-Sep-16 5:08 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 15-Sep-16 | Market Option Sale (Planned) | 59,369 | $11.73 | $696,398.00 | (21%) 288.14K to 228.77K | (103%) |
| 16-Sep-16 5:08 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 15-Sep-16 | Option Exercise | 59,369 | $7.82 | $464,266.00 | 26% 228.77K to 288.14K | |
| 23-Aug-16 4:12 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 22-Aug-16 | Market Sale (Planned) | 19,436 | $10.47 | $203,538.00 | (8%) 248.21K to 228.77K | (127%) |
| 15-Aug-16 4:16 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 12-Aug-16 | Option Exercise | 25,000 | $7.69 | $192,250.00 | 10% 248.21K to 273.21K | |
| 15-Aug-16 4:16 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 12-Aug-16 | Market Option Sale (Planned) | 25,000 | $10.50 | $262,500.00 | (9%) 273.21K to 248.21K | (127%) |
| 25-Jul-16 4:39 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 22-Jul-16 | Market Sale (Planned) | 18,286 | $8.11 | $148,230.00 | (7%) 266.49K to 248.21K | (194%) |
| 14-Jul-16 4:23 PM View: | Panayiotopoulos Paris President and CEO Director | Ariad Pharmaceuticals Inc. (ARIA) | 13-Jul-16 | Payment of Exercise | 28,611 | $7.14 | $204,283.00 | (18%) 154.69K to 126.08K | (233%) |
| 14-Jul-16 4:23 PM View: | Panayiotopoulos Paris President and CEO Director | Ariad Pharmaceuticals Inc. (ARIA) | 13-Jul-16 | Option Exercise | 66,600 | -- | -- | 76% 88.09K to 154.69K | |
| 05-Jul-16 4:07 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 01-Jul-16 | Option Exercise | 61,422 | $3.88 | $238,585.00 | 23% 266.49K to 327.92K | |
| 05-Jul-16 4:07 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 01-Jul-16 | Market Option Sale (Planned) | 61,422 | $7.48 | $459,634.00 | (19%) 327.92K to 266.49K | (218%) |
| 29-Jun-16 4:25 PM View: | Cole Hugh M SVP, Chief Business Officer | Ariad Pharmaceuticals Inc. (ARIA) | 28-Jun-16 | Market Option Sale | 6,012 | $7.05 | $42,384.60 | (17%) 35.93K to 29.92K | (238%) |
| 29-Jun-16 4:25 PM View: | Cole Hugh M SVP, Chief Business Officer | Ariad Pharmaceuticals Inc. (ARIA) | 27-Jun-16 | Option Exercise | 19,166 | -- | -- | 114% 16.76K to 35.93K | |
| 23-Jun-16 4:11 PM View: | Clackson Timothy P President, R&D, CSO | Ariad Pharmaceuticals Inc. (ARIA) | 22-Jun-16 | Market Sale | 23,999 | $7.28 | $174,638.00 | (8%) 288.74K to 264.74K | (227%) |
| 15-Jun-16 4:19 PM View: | Lavidas Athanese Director | Ariad Pharmaceuticals Inc. (ARIA) | 15-Jun-16 | Option Exercise | 46,250 | $6.55 | $302,788.00 | 35% 131.63K to 177.88K | |
| 15-Jun-16 4:19 PM View: | Lavidas Athanese Director | Ariad Pharmaceuticals Inc. (ARIA) | 15-Jun-16 | Market Option Sale | 46,250 | $8.24 | $381,137.00 | (26%) 177.88K to 131.63K | (189%) |
| 15-Jun-16 4:19 PM View: | Lavidas Athanese Director | Ariad Pharmaceuticals Inc. (ARIA) | 14-Jun-16 | Option Exercise | 20,000 | $6.44 | $128,800.00 | 15% 131.63K to 151.63K |
